News Releases


Medtronic Named One of the World’s Most Admired Companies

February 19, 2016

Dublin - February 19, 2016 - Fortune magazine announced today that Medtronic is included on its list of the World's Most Admired Companies for 2016. The list is considered one of the leading measures of corporate reputation among the world’s largest companies. Medtronic is ranked second in the Medical Products and Equipment category.

Read more >

Medtronic's iPro(TM)2 Professional CGM Shows Benefits for People with Type 2 Diabetes

February 5, 2016

MILAN - February 5, 2016 - A retrospective analysis of the iPro2 Professional CGM from Medtronic plc (NYSE:MDT), the global leader in medical technology, demonstrates that patients with type 2 diabetes experience high rates of glycemic variability, hypoglycemia and hyperglycemia regardless of whether they manage their diabetes with diet/exercise, oral medication or insulin. Using this actionable iPro2 Professional CGM information, physicians can make therapy adjustments, recommendations and educational decisions for their patients to help improve glucose control. The results of the analysis were featured in an oral presentation at the 9th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2016).

Read more >

Medtronic and Chengdu Sign Insulin Pump Manufacturing Agreement

January 11, 2016

DUBLIN and CHENGDU, China - January 11, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, has formed a partnership with the Chengdu municipal government to manufacture and deploy advanced diabetes therapies in Chengdu, China.

Read more >

CES Puts IBM and MDT In Spotlight - Partners Unveil Plans For Cognitive Diabetes App

January 7, 2016

Las Vegas, NV – January 7, 2016 - IBM CEO Ginni Rometty and Medtronic CEO Omar Ishrak took center stage during a keynote address at the 2016 Consumer Electronics Show (CES) in Las Vegas to unveil the latest advances in applying cognitive computing to diabetes management.

Read more >

Medtronic Expands Access to Type 2 Diabetes Products with Selection of Henry Schein as Exclusive Distributor

December 2, 2015

DUBLIN and MELVILLE, N.Y. - December 2, 2015 - Medtronic plc (NYSE:MDT), the global leader in medical technology, has selected Henry Schein Medical, the U.S. Medical business of Henry Schein, Inc. (NASDAQ: HSIC), as an exclusive distributor of selected diabetes products to primary care physicians (PCPs) in the U.S. The exclusive distribution agreement broadens access to Medtronic solutions for people with type 2 diabetes under the care of primary care physicians who oversee their diabetes management. Henry Schein Medical is a leading provider of health care products and services to office-based medical practitioners in the U.S.

Read more >

View all Announcements >

Media Inquiries

For media inquiries pertaining to the Diabetes Group of Medtronic, please contact:

Amanda Sheldon
Director of Digital Marketing and Communications

For all other media inquiries please select the appropriate Global Public and Media Relations contact